Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer
- 6 March 2003
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (6) , 3450-3454
- https://doi.org/10.1073/pnas.0537900100
Abstract
Fabry disease is an X-linked recessive inborn metabolic disorder characterized by systemic and vascular accumulation of globotriaosylceramide (Gb 3 ) caused by a deficiency of the lysosomal enzyme α-galactosidase A (α-gal A). The condition is associated with an increased morbidity and mortality due to renal failure, cardiac disease, and early onset of stroke. Hemizygous males are primarily affected clinically with variable expression in heterozygous females. Gene-therapy trials have been initiated recently in α- gal A knockout mouse models of Fabry disease by using a variety of viral vectors. In the present investigation we administered single i.v. injections of 1 × 10 10 genomes of recombinant adeno-associated virus (rAAV) encoding the human α- gal A gene driven by a modified chicken β-actin (CAG) promoter to α- gal A knockout (Fabry) mice. Transgenic mice were analyzed for expression of α-gal A activity and Gb 3 levels in liver, kidney, heart, spleen, small intestine, lung, and brain. Administration of the rAAV-CAG-hAGA vector resulted in stable expression of α-gal A in organs of the Fabry mice for >6 months. α-Gal A activity in the organs became equal to or higher than that of wild-type mice. Accumulated Gb 3 in the liver, heart, and spleen was reduced to that of wild-type mice with lesser but significant reductions in kidney, lung, and small intestine. Injection of the rAAV-CAG-hAGA construct into skeletal muscle did not result in expression of α- gal A in it or in other tissues. This study provides a basis for a simple and efficient gene-therapy approach for patients with Fabry disease and is indicative of its potential for the treatment of other lysosomal storage disorders.Keywords
This publication has 33 references indexed in Scilit:
- Adenovirus-Transduced Lung as a Portal for Delivering α-Galactosidase A into Systemic Circulation for Fabry DiseaseMolecular Therapy, 2002
- Correction of the Nonlinear Dose Response Improves the Viability of Adenoviral Vectors for Gene Therapy of Fabry DiseaseHuman Gene Therapy, 2002
- High Overexpression of the Human α-Galactosidase a Gene Driven by Its Promoter in Transgenic Mice: Implications for the Treatment of Fabry DiseaseJournal of Investigative Medicine, 2002
- A Recombinant Baculovirus-ExpressedPlasmodium falciparumReceptor-Binding Domain of Erythrocyte Binding Protein EBA-175 Biologically Mimics Native ProteinInfection and Immunity, 2000
- Enhanced Expression of Transgenes from Adeno-Associated Virus Vectors with the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element: Implications for Gene TherapyHuman Gene Therapy, 1999
- Neonatal Intramuscular Injection with Recombinant Adeno-Associated Virus Results in Prolonged beta-Glucuronidase Expression in Situ and Correction of Liver Pathology in Mucopolysaccharidosis Type VII MiceHuman Gene Therapy, 1999
- Complete correction of acid α-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscleGene Therapy, 1998
- Correction of Ornithine Transcarbamylase Deficiency in AdultspfashMice and in OTC-Deficient Human Hepatocytes with Recombinant Adenoviruses Bearing the CAG PromoterHuman Gene Therapy, 1996
- Immunofluorescence imaging diagnosis of Fabry heterozygotes using confocal laser scanning microscopyClinical Genetics, 1993
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991